About
Skape develops AI-designed biologics by combining de novo protein design and high-throughput in-cell screening to create functional miniproteins targeting GPCRs and other challenging membrane receptors for drug discovery.
Explore Skape's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.